The DNA methylome of benign and malignant parathyroid tumors
✍ Scribed by Lee F. Starker; Jessica Svedlund; Robert Udelsman; Henning Dralle; Göran Åkerström; Gunnar Westin; Richard P. Lifton; Peyman Björklund; Tobias Carling
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 648 KB
- Volume
- 50
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The role of DNA methylation of CpG islands in parathyroid tumorigenesis has not been analyzed in an unbiased, systematic fashion. DNA was isolated from normal and pathologic parathyroid tissues, bisulphite modified and analyzed using the Infinium HumanMethylation27 BeadChip. Distinct hierarchical clustering of genes with altered DNA methylation profiles in normal and pathologic parathyroid tissue was evident. Comparing normal parathyroid tissue with parathyroid adenomas, 367 genes were significantly altered, while 175 genes significantly differed when comparing parathyroid carcinomas and normal parathyroid tissues. A comparison between parathyroid adenomas and parathyroid carcinomas identified 263 genes with significantly distinct methylation levels. Results were confirmed for certain genes in a validation cohort of 40 parathyroid adenomas by methylation‐specific PCR. Genes of known or putative importance in the development of parathyroid tumors showed significant and frequent hypermethylation. DNA hypermethylation of CDKN2B, CDKN2A, WT1, SFRP1, SFRP2, and SFRP4 was associated with reduced gene expression in both benign and malignant parathyroid tumors. Treatment with 5‐aza‐2′‐deoxycytidine of primary cell cultures restores expression of hypermethylated genes in benign and malignant parathyroid tumors. In conclusion, the unbiased, genome‐wide study of the parathyroid tumor DNA methylome identified a number of genes with altered DNA methylation patterns of putative importance to benign and malignant parathyroid tumorigenesis. © 2011 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
The relevance of the DNA index (DI) to malignancy grading and the relationships between mitotic score, Ki-67 score, and the proportion of cells in the G1-phase (G1PF) of the cell cycle, as proliferative indicators, were investigated in benign (n = 8) and malignant (n = 46) soft tissue sarcomas. Alth
The clinical records of all patients with granular cell tumor seen at our institution over a 20-year period were reviewed. Three patients with malignant, and 37 with benign tumor, were identified. Eleven patients had multiple benign lesions. Three had a history of familial occurrence. Clinical and p
Reported are first experiences with Nd:YAG laser treatment of benign, semimalignant, and malignant skin tumors in 90 patients. Treated lesions included condylomata acuminata, basal cell carcinomas, solar keratosis, squamous cell carcinomas, and secondary malignant skin tumors. First clinical and his